Literature DB >> 25644539

Adenosine derived from ecto-nucleotidases in calcific aortic valve disease promotes mineralization through A2a adenosine receptor.

Ablajan Mahmut1, Marie-Chloé Boulanger1, Rihab Bouchareb1, Fayez Hadji1, Patrick Mathieu2.   

Abstract

AIMS: In this study, we sought to determine the role of ecto-nucleotidases and adenosine receptors in calcific aortic valve disease (CAVD). The expression of ecto-nucleotidases, which modify the levels of extracellular nucleotides/nucleosides, may control the mineralization of valve interstitial cells (VICs). We hypothesized that expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), which generates AMP, and 5'-nucleotidase (CD73), an enzyme using AMP as a substrate to produce adenosine, may co-regulate the mineralization of the aortic valve. METHODS AND
RESULTS: We have investigated the expression of NPP1 and 5'-nucleotidase in CAVD tissues and determined the role of these ecto-nucleotidases on the mineralization of isolated VICs. In CAVD tissues (stenotic and sclerotic), we documented that NPP1 and 5'-nucleotidase were overexpressed by VICs. In isolated VICs, we found that mineralization induced by adenosine triphosphate was decreased by silencing NPP1 and 5'-nucleotidase, suggesting a role for adenosine. Adenosine and specific A2a adenosine receptor (A2aR) agonist increased the mineralization of VICs. Silencing of A2aR in human VICs and the use of A2aR(-/-) mouse VICs confirmed that A2aR promotes the mineralization of cells. Also, A2aR-mediated mineralization was negated by the transfection of a mutant dominant-negative Gαs vector. Through several lines of evidence, we next documented that adenosine stimulated the mineralization of VICs through a cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway, and found that CREB positively regulated the expression of NPP1 in a positive feedback loop by physically interacting with the promoter.
CONCLUSION: Expression of NPP1 and 5'-nucleotidase by VICs promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  5′-nucleotidase; A2a receptor; Adenosine; Aortic stenosis; Biomineralization; CD73; CREB; Calcific aortic valve disease; Calcific aortic valve stenosis; ENPP1; Ectopic mineralization; NPP1; NT5E; PKA

Mesh:

Substances:

Year:  2015        PMID: 25644539     DOI: 10.1093/cvr/cvv027

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  13 in total

1.  Regulation of CD73 in the development of lower limb atherosclerosis.

Authors:  Juho Jalkanen; Maija Hollmén; Sirpa Jalkanen; Harri Hakovirta
Journal:  Purinergic Signal       Date:  2016-11-10       Impact factor: 3.765

Review 2.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

3.  OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway.

Authors:  Mohamed Jalloul Nsaibia; Marie-Chloé Boulanger; Rihab Bouchareb; Ghada Mkannez; Khai Le Quang; Fayez Hadji; Deborah Argaud; Abdellaziz Dahou; Yohan Bossé; Marlys L Koschinsky; Philippe Pibarot; Benoit J Arsenault; André Marette; Patrick Mathieu
Journal:  Cardiovasc Res       Date:  2017-09-01       Impact factor: 10.787

4.  RBM20S639G mutation is a high genetic risk factor for premature death through RNA-protein condensates.

Authors:  Chunyan Wang; Yanghai Zhang; Mei Methawasin; Camila Urbano Braz; Jeffrey Gao-Hu; Betty Yang; Joshua Strom; Jochen Gohlke; Timothy Hacker; Hasan Khatib; Henk Granzier; Wei Guo
Journal:  J Mol Cell Cardiol       Date:  2022-01-15       Impact factor: 5.000

Review 5.  Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.

Authors:  Harry Z E Greenberg; Guoan Zhao; Ajay M Shah; Min Zhang
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

6.  CHDGKB: a knowledgebase for systematic understanding of genetic variations associated with non-syndromic congenital heart disease.

Authors:  Lan Yang; Yang Yang; Xingyun Liu; Yongquan Chen; Yalan Chen; Yuxin Lin; Yan Sun; Bairong Shen
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

7.  CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease.

Authors:  Igor Kudryavtsev; Maria Serebriakova; Ekaterina Zhiduleva; Patimat Murtazalieva; Vladislav Titov; Anna Malashicheva; Anastasya Shishkova; Daria Semenova; Olga Irtyuga; Dmitry Isakov; Lubov Mitrofanova; Olga Moiseeva; Alexey Golovkin
Journal:  Front Genet       Date:  2019-07-25       Impact factor: 4.599

8.  The new insight into extracellular NAD+ degradation-the contribution of CD38 and CD73 in calcific aortic valve disease.

Authors:  Patrycja Jablonska; Barbara Kutryb-Zajac; Paulina Mierzejewska; Agnieszka Jasztal; Barbara Bocian; Romuald Lango; Jan Rogowski; Stefan Chlopicki; Ryszard T Smolenski; Ewa M Slominska
Journal:  J Cell Mol Med       Date:  2021-06-18       Impact factor: 5.310

9.  Nucleotide Catabolism on the Surface of Aortic Valve Xenografts; Effects of Different Decellularization Strategies.

Authors:  Barbara Kutryb-Zajac; Ada H Y Yuen; Zain Khalpey; Paulina Zukowska; Ewa M Slominska; Patricia M Taylor; Steven Goldstein; Albert E Heacox; Marialuisa Lavitrano; Adrian H Chester; Magdi H Yacoub; Ryszard T Smolenski
Journal:  J Cardiovasc Transl Res       Date:  2016-02-01       Impact factor: 4.132

Review 10.  MicroRNAs in Valvular Heart Diseases: Potential Role as Markers and Actors of Valvular and Cardiac Remodeling.

Authors:  Cécile Oury; Laurence Servais; Nassim Bouznad; Alexandre Hego; Alain Nchimi; Patrizio Lancellotti
Journal:  Int J Mol Sci       Date:  2016-07-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.